Sign in

You're signed outSign in or to get full access.

WI

WW INTERNATIONAL, INC. (WW)·Q4 2025 Earnings Summary

Executive Summary

  • WW has not yet reported Q4 2025 results; there is no 8‑K 2.02 or earnings call transcript available as of today. The latest primary sources are Q3 2025 (reported Nov 6) and Q2 2025 (Aug 11), plus Q4 2024 (reported Feb 27, 2025) for year‑over‑year context .
  • In Q3 2025, WW delivered strong profitability despite revenue headwinds: Adjusted EBITDA margin 24.9% and operating income of $8.0M; management raised FY2025 guidance to Revenue $695–$700M and Adjusted EBITDA $145–$150M .
  • Clinical momentum and cost discipline offset Behavioral weakness: Clinical subscription revenue +35% y/y; ARPU +9% y/y, while Behavioral subscribers fell 20% y/y .
  • Near‑term catalysts into peak season: brand refresh, app/website re‑platform, and anticipated oral GLP‑1 launches early 2026 (Novo/Lilly) that management expects to open a new top‑funnel for clinical growth .

What Went Well and What Went Wrong

What Went Well

  • Clinical revenue growth and retention: Clinical subscription revenues rose 35.3% y/y; WW converted ~20% of members previously on compounded semaglutide to branded/oral medications, exceeding expectations .
  • Profitability resilience and guidance raised: Adjusted EBITDA margin was 24.9% and full‑year guidance was tightened higher (Revenue $695–$700M; Adj. EBITDA $145–$150M), signaling execution discipline .
  • Strategic clarity and digital modernization: CEO emphasized WW’s integrated clinical-behavioral model and the app/website replatforming to deliver a unified, AI‑enabled member experience in time for peak season .

Management quotes:

  • “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market.” (CEO) .
  • “Our healthier balance sheet has enabled us to begin investing in growth opportunities, while continuing to deliver strong profitability.” (CFO) .

What Went Wrong

  • Behavioral pressure continues: End‑of‑period Behavioral subscribers fell 20.2% y/y and Behavioral subscription revenues declined 15.7% y/y in Q3 2025 .
  • GAAP loss driven by tax expense: Q3 net loss was $(57.5)M with a $53.2M tax provision; diluted EPS was $(5.76) due to fresh‑start accounting and share count mechanics post‑reorganization .
  • Sequential ARPU softness: ARPU declined sequentially due to higher clinical 12‑month commitment plans and promotions; management also flagged Q4 adjusted EBITDA will decline vs Q3 on increased marketing ahead of peak .

Financial Results

Note: Q4 2025 has not been reported; comparisons use Q4 2024 (y/y), Q2 2025 (prior quarter), and Q3 2025 (latest).

MetricQ4 2024Q2 2025 (Combined)Q3 2025
Revenue ($USD Millions)$184.4 $189.2 $172.1
Diluted EPS ($USD)$0.31 N/A (predecessor/successor) $(5.76)
Gross Margin (%)69.7% 73.7% (Predecessor) 72.1%
Operating Income ($USD Millions)$36.2 $41.4 (Predecessor) $8.0
Adjusted EBITDA ($USD Millions)$46.3 $65.0 (=$61.0 Predecessor + $4.0 Successor )$43.0
Adjusted EBITDA Margin (%)25.1% 34.4% (Predecessor) 24.9%

Segment subscription revenue breakdown:

SegmentQ4 2024Q2 2025 (Combined)Q3 2025
Behavioral Subscription Revenues ($USD Millions)~$161.2 (=$181.7 total subscription − $20.5 clinical) $157.3 $145.2
Clinical Subscription Revenues ($USD Millions)$20.5 $30.6 $25.8
Other Revenues ($USD Millions)$2.7 $1.3 $1.2

KPIs:

KPIQ4 2024Q2 2025 (Combined)Q3 2025
End of Period Subscribers (Total)3.3M 3,167k 2,986k
End of Period Behavioral SubscribersN/A (declined y/y) 3,040k 2,862k
End of Period Clinical Subscribers92k 127k 124k
Monthly Subscription Revenues Per Avg Subscriber (ARPU, $USD)$16.99 $18.97 $18.52

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Total Revenues ($USD Millions)FY 2025$685–$700M $695–$700M Raised to high end
Adjusted EBITDA ($USD Millions)FY 2025$140–$150M $145–$150M Raised to high end

Management also indicated Q4 adjusted EBITDA will be lower vs Q3 due to increased marketing ahead of peak season .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2025)Previous Mentions (Q3 2025)Current Period (Q4 2025)Trend
Integrated clinical + behavioral modelEmphasized holistic model; ceased compounded semaglutide May 22; expanding dietitian network Reinforced model efficacy; clinical care plus behavioral support with data showing superior outcomes Not yet reported; strategy unchangedStrengthening
Digital replatform (App/Website)Announced foundational stack improvements; AI and data leverage App/website replatform targeted for early next year peak; AI personalization Not yet reported; first release expected around peakExecution progressing
Partnerships (Novo/Lilly/Amazon)Formal integrations for medication access (CenterWell/LillyDirect) NovoCare/LillyDirect integrations; new Amazon Pharmacy collaboration Not yet reportedExpanding access, lower friction
Menopause program“Coming soon” curated program Launched with clinical/non‑clinical versions; positive engagement Not yet reportedNew adjacencies scaling
Marketing/brand refreshRepositioning; lighter spend during reorg Comprehensive brand refresh; heavier Q4 spend into peak Not yet reportedSpending up, brand modernization
Debt/Balance sheetReduced debt by ~$1.15B; cash dynamics explained Term loan $465M; cash $170M; net debt down ~80% from Q4 2024 Not yet reportedImproved flexibility

Management Commentary

  • CEO: “The future of weight management will be built on an integrated approach that pairs clinical care and medication access with structured nutrition, movement, and accountability.” .
  • CEO: “Looking forward, we’re focused on four key priorities… deliver an engaging, unified end‑to‑end member experience… grow emerging medical… modernize brand… drive operational improvements.” .
  • CFO: “Adjusted EBITDA was $43M… we expect adjusted EBITDA to decline in Q4 compared to Q3, reflecting the increase in marketing… while still maintaining a strong margin profile.” .
  • Q4 2024 press release context: “Gross Margin in Q4 2024 was 69.7%… Adjusted Gross Margin was 69.1%… Operating Income was $36.2M… Adjusted EPS was $0.32.” .

Q&A Highlights

  • Product integration and app timeline: First version of the redesigned app targeted for early next year, in time for peak season .
  • Pharmacy/access partnerships: Amazon Pharmacy integration adds real‑time availability, automatic coupons, and Prime shipping; NovoCare/LillyDirect cash‑pay integrations continue to reduce friction .
  • Clinical retention/transition: ~20% of compounded semaglutide users transitioned to branded/oral meds; ARPU decline was acceptable given improved retention via 12‑month commitments .
  • Peak season positioning: Brand refresh and anticipated oral GLP‑1 launches expected to open a new top funnel of clinically interested members .

Estimates Context

  • S&P Global Wall Street consensus for Q4 2025 is unavailable at this time due to data access limits. Values retrieved from S&P Global are unavailable today.
  • For Q4 2024, third‑party coverage indicated revenue of $184.4M vs analyst estimates of ~$175.7M and adjusted EPS $0.32 vs ~$0.07, but these are not S&P Global figures . Use caution; S&P Global consensus should be the anchor when available.

Key Takeaways for Investors

  • The absence of Q4 2025 results means focus shifts to trajectory: Clinical growth (+35% y/y in Q3) and high‑teens to mid‑20s adjusted EBITDA margins underpin FY2025 guidance raised to the high end .
  • Behavioral acquisition remains a headwind; watch for Q1 peak season subscriber trends post brand refresh and app/website launch to validate stabilization efforts .
  • Clinical access tailwinds from oral GLP‑1 launches and price competition could expand WW’s funnel; partnerships (Novo/Lilly/Amazon) reduce friction and may drive conversion/retention .
  • Cost discipline remains evident, but Q4 profitability will step down on elevated marketing; monitor FY margin integrity vs guidance .
  • Balance sheet reset (term loan $465M, cash $170M in Q3) provides operating flexibility; annual excess cash sweep begins June 2026 .
  • KPI watch‑items: clinical subscriber trend (Q3 trough expected), ARPU mix shift, and end‑of‑period Behavioral subscriber stabilization .
  • Estimate recalibration likely awaits Q4 print; use S&P Global consensus when accessible; meanwhile, operational execution into peak and clinical momentum are the near‑term stock drivers .